Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1975 Oct;72(10):4128–4132. doi: 10.1073/pnas.72.10.4128

A unique complement derived chemotactic factor for tumor cells.

A G Romualdez Jr, P A Ward
PMCID: PMC433152  PMID: 172896

Abstract

A factor chemotactic for Walker carcinosarcoma and Novikoff hepatoma tumor cells can be generated by incubation of serum with an extract from tumor cells. The chemotactic factor has no activity for neutrophilic leukocytes, and three factors chemotactic for leukocytes are not chemotactic for tumor cells. By the use of complement deficient serums as well as purified complement components, the chemotactic factor for tumor cells has been found to be a fragment of the fifth component (C5) of complement and appears to result from direct interaction of C5 with an enzyme in the extract. The chemotactic factor for tumor cells can be classified as a functionally unique fragment of C5 that may significantly influence the behavior of tumor cells in vivo.

Full text

PDF
4128

Images in this article

4131Image
on p.4131

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABERCROMBIE M., AMBROSE E. J. Interference microscope studies of cell contacts in tissue culture. Exp Cell Res. 1958 Oct;15(2):332–345. doi: 10.1016/0014-4827(58)90034-x. [DOI] [PubMed] [Google Scholar]
  2. ABERCROMBIE M., AMBROSE E. J. The surface properties of cancer cells: a review. Cancer Res. 1962 Jun;22:525–548. [PubMed] [Google Scholar]
  3. Brier A. M., Snyderman R., Mergenhagen S. E., Notkins A. L. Inflammation and herpes simplex virus: release of a chemotaxis-generating factor from infected cells. Science. 1970 Dec 4;170(3962):1104–1106. doi: 10.1126/science.170.3962.1104. [DOI] [PubMed] [Google Scholar]
  4. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  5. Hill J. H., Ward P. A. C3 leukotactic factors produced by a tissue protease. J Exp Med. 1969 Sep 1;130(3):505–518. doi: 10.1084/jem.130.3.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. NILSSON U. R., MUELLER-EBERHARD H. J. ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med. 1965 Aug 1;122:277–298. doi: 10.1084/jem.122.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. O'MEARA R. A. Coagulative properties of cancers. Ir J Med Sci. 1958 Oct;394:474–479. [PubMed] [Google Scholar]
  8. Ozaki T., Yoshida K., Ushijima K., Hayashi H. Studies on the mechanisms of invasion in cancer. II. In vivo effects of a factor chemotactic for cancer cells. Int J Cancer. 1971 Jan 15;7(1):93–100. doi: 10.1002/ijc.2910070111. [DOI] [PubMed] [Google Scholar]
  9. Rother K., Rother U., Müller-Eberhard H. J., Nilsson J. R. Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med. 1966 Oct 1;124(4):773–785. doi: 10.1084/jem.124.4.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Snyderman R., Shin H. S., Phillips J. K., Gewurz H., Mergenhagen S. E. A neutrophil chemotatic factor derived from C'5 upon interaction of guinea pig serum with endotoxin. J Immunol. 1969 Sep;103(3):413–422. [PubMed] [Google Scholar]
  11. Snyderman R., Shin H., Dannenberg A. M., Jr Macrophage proteinase and inflammation: the production of chemotactic activity from the fifth complement by macrophage proteinase. J Immunol. 1972 Oct;109(4):896–898. [PubMed] [Google Scholar]
  12. Sorkin E., Stecher V. J., Borel J. F. Chemotaxis of leucocytes and inflammation. Ser Haematol. 1970;3(1):131–162. [PubMed] [Google Scholar]
  13. WARD P. A., COCHRANE C. G. BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. J Exp Med. 1965 Feb 1;121:215–234. doi: 10.1084/jem.121.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. WARD P. A., COCHRANE C. G., MUELLER-EBERHARD H. J. THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO. J Exp Med. 1965 Aug 1;122:327–346. doi: 10.1084/jem.122.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ward P. A. Chemotoxis of mononuclear cells. J Exp Med. 1968 Nov 1;128(5):1201–1221. doi: 10.1084/jem.128.5.1201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ward P. A., Hill J. H. Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis. J Immunol. 1972 May;108(5):1137–1145. [PubMed] [Google Scholar]
  17. Ward P. A., Lepow I. H., Newman L. J. Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol. 1968 Apr;52(4):725–736. [PMC free article] [PubMed] [Google Scholar]
  18. Ward P. A. Leukotaxis and leukotactic disorders. A review. Am J Pathol. 1974 Dec;77(3):520–538. [PMC free article] [PubMed] [Google Scholar]
  19. Ward P. A., Newman L. J. A neutrophil chemotactic factor from human C'5. J Immunol. 1969 Jan;102(1):93–99. [PubMed] [Google Scholar]
  20. Ward P. A., Zvaifler N. J. Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest. 1971 Mar;50(3):606–616. doi: 10.1172/JCI106531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Yoshida K., Ozaki T., Ushijima K., Hayashi H. Studies on the mechanisms of invasion in cancer. I. Isolation and purification of a factor chemotactic for cancer cells. Int J Cancer. 1970 Jul 15;6(1):123–132. doi: 10.1002/ijc.2910060116. [DOI] [PubMed] [Google Scholar]
  22. ZEIDMAN I. The fate of circulating tumors cells. I. Passage of cells through capillaries. Cancer Res. 1961 Jan;21:38–39. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES